

1 Treatment of irritant contact dermatitis in healthcare settings during the COVID19 pandemic: 2 The emollient Dermol 500 exhibits virucidal activity against influenza A virus and SARS-CoV-2.

3
4 *Christine T. Styles¹, Michael Vanden Oever¹, Jonathan Brown¹, Sweta Rai², Sarah Walsh², Finola M. Ryan^{3,4},
5 Wendy S. Barclay¹ and Rachel S. Edgar^{1*}*

6 ¹Department of Infectious Diseases, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK.

7 ²Department of Dermatology, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS.

8 ³Department of Occupational Health & Wellbeing, Jennie Lee House, King's College Hospital NHS Foundation Trust,
9 London SE5 8AD, UK.

10 ⁴Department of Targeted Intervention, University College London, Gower Street, London WC1E 6BT, UK.

11 *Correspondence to Rachel S. Edgar; rachel.edgar@imperial.ac.uk

12

13 Key words: virucidal, antiviral, Dermol 500, antimicrobial emollient, influenza virus, SARS-CoV-2, COVID19,
14 benzalkonium chloride (BAK), chlorohexidine dihydrochloride (CD), work-related contact dermatitis.

15

16 KEY MESSAGES

17

18 1. What is already known about this subject?

19 • Work-related contact dermatitis is a prominent issue among healthcare workers, and likely
20 exacerbated by the enhanced hand hygiene and personal protective equipment required to control
21 infection during the COVID19 pandemic.

22 • The antimicrobial lotion Dermol 500 is frequently prescribed as an emollient and soap substitute to
23 help prevent and treat dermatitis, but its use during the COVID19 pandemic was not advised as its
24 capacity to inactivate viruses was unknown.

25 2. What are the new findings?

26 • Increased incidence of irritant contact dermatitis was recorded amongst healthcare workers at King's
27 College Hospital NHS Foundation Trust in 2020 compared to 2019.

28 • Dermol 500 lotion and its antimicrobial components, benzalkonium chloride (BAK) and chlorohexidine
29 dihydrochloride (CD), exhibit virucidal activity against influenza A virus and SARS-CoV-2, the virus
30 responsible for COVID19 pandemic.

31 3. How might this impact policy or clinical practice in the foreseeable future?

32 • Our results demonstrate that Dermol 500 can be safely used as a soap substitute to treat work-related
33 contact dermatitis in clinical care settings during the COVID19 pandemic.

34 • Employers can meet their obligations under COSHH to eliminate workplace exposure to a harmful
35 substance and substitute with an alternative product for hand hygiene.

36

37 ABSTRACT

38

39 **Objectives:** To investigate whether the antimicrobial emollient Dermol 500 and its active components,
40 benzalkonium chloride (BAK) and chlorohexidine dihydrochloride (CD), exhibit virucidal activity thus
41 informing whether Dermol 500 is a suitable soap substitute for use during the COVID19 pandemic, to combat
42 the increased incidence of work-related contact dermatitis in clinical settings that we report here.

43

44 **Methods:** Inactivation of influenza A virus and SARS-CoV-2 by Dermol 500 and the independent and
45 combined virucidal activity of the Dermol 500 components BAK and CD was assessed by influenza A virus and
46 SARS-CoV-2 infectivity assays. Viruses were treated with concentrations of BAK and CD comparable to
47 Dermol 500, and lower, and infectivity of the viruses assessed by titration.

48

49 **Results:** Dermol 500 exhibits comparable virucidal activity to alcohol-based sanitisers against influenza A
50 virus and SARS-CoV-2. In addition, the Dermol 500 components BAK and CD exhibit independent and
51 synergistic virucidal activity against influenza A virus and SARS-CoV-2, the causative agent of COVID19.

52 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

53 **Conclusions:** The synergistic virucidal activity of the Dermol 500 components BAK and CD makes Dermol 500
54 suitable as a soap substitute to treat and prevent work-related contact dermatitis in healthcare settings.

55 ABBREVIATIONS

56		
57	IAV:	Influenza A virus
58	SARS-CoV-2:	Severe acute respiratory syndrome coronavirus 2
59	PPE:	Personal protective equipment
60	COSHH:	Control of Substances Hazardous to Health Regulations
61	RIDDOR:	Reporting of Injuries, Diseases and Dangerous Occurrences Regulations
62	BAK:	Benzalkonium chloride
63	CD:	Chlorohexidine dihydrochloride
64	RT:	Room temperature
65	SFM:	Serum-free medium
66	CCV:	Canine coronavirus
67	HSV1:	Herpes simplex virus 1
68	HIV:	Human immunodeficiency virus
69	CMV:	Cytomegalovirus
70	RSV:	Respiratory syncytial virus
71	SARS-CoV-1:	Severe acute respiratory syndrome coronavirus 1


73 INTRODUCTION

74
75 Hand hygiene is imperative in healthcare settings and hand washing with soap or use of alcohol-based hand
76 sanitisers are advised worldwide to assist infection control¹. However, such hand hygiene measures and use
77 of personal protective equipment (PPE) such as gloves and masks can precipitate irritant contact dermatitis².
78 This skin condition is characterised by damage to the stratum corneum layer of the epidermis, resulting in
79 cracked, dry and itchy skin with impaired barrier function, and advances to severe irritation and
80 inflammation³. Following the development of dermatitis there is an elevated risk of bacterial colonisation
81 and subsequent transmission to other healthcare workers or patients.

82
83 Work-related contact dermatitis in healthcare professionals has been exacerbated by the infection control
84 measures required during the COVID19 pandemic. 84.6% of surveyed Wuhan healthcare workers reported
85 adverse skin reactions attributed to increased hand washing frequency⁴. Since March 2020, we have
86 observed a sharp increase in NHS staff presenting with irritant hand dermatitis (Figure 1)⁵. Between 26th
87 March – 6th May, 468 staff within King’s College Hospital NHS Foundation Trust presenting to a staff
88 dermatology clinic were diagnosed with irritant hand dermatitis. For comparison, only 8 staff had this
89 diagnosis recorded over the same time period in 2019 at the occupational health department of the hospital.
90 A 9.5 fold increase in irritant contact dermatitis diagnoses has been observed overall in 2020 compared to
91 2019 (Figure 1C), with significant increases in both occupational health walk-in cases and those diagnosed
92 following management referral (Figures 1A and B).

93
94 Although dermatitis is a prominent issue for healthcare workers, it is manageable with appropriate
95 interventions³. Under UK health and safety law, legislation details that employers have a duty of care and
96 statutory legal obligation to employees to minimise and avoid health problems caused by work, including
97 development of skin conditions such as work-related dermatitis⁶. ‘The Control of Substances Hazardous to
98 Health Regulations, (COSHH) 2002, (as amended)’ requires employers to identify substances that may be
99 hazardous to health, assess risks and implement adequate control measures to control exposure and protect
100 health⁷. Indeed, if the contact dermatitis is considered solely caused by work, it is reportable under the
101 ‘Reporting of Injuries, Diseases and Dangerous Occurrences Regulations (RIDDOR) 2013’^{8,9}. Prior to the
102 COVID19 pandemic, the use of soap substitutes and emollients was advised to treat work-related contact
103 dermatitis in healthcare workers by the Royal College of Physicians and other medical bodies², meeting the
104 COSHH requirement to eliminate exposure to the hazardous substance and substitute with an alternative.
105 Notably, Dermol 500 lotion is usually prescribed as an antimicrobial emollient and soap substitute to aid skin
106 conditions such as dermatitis¹⁰. However, due to a lack of evidence regarding whether Dermol 500 can
107 inactivate virus particles, its use in clinical settings was discouraged during the COVID19 pandemic¹¹.

Figure 1. Comparative analysis of staff diagnosed with irritant contact dermatitis at King's College Hospital NHS Foundation Trust during 2019 and 2020.



108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130

Dermol 500 contains the antimicrobial components benzalkonium chloride (BAK) and chlorohexidine dihydrochloride (CD)¹⁰, which both have broad and well established antimicrobial activity¹²⁻¹³. This includes activity against the bacterial genera *Chlamydia*¹⁴, *Pseudomonas*¹⁵, *Streptococcus*¹⁶ and *Staphylococcus*¹⁷, amongst others. BAK has been independently shown to exhibit virucidal activity against various enveloped viruses, including Canine coronavirus (CCV)¹⁸, herpes simplex virus 1 (HSV1)¹⁹, human immunodeficiency virus (HIV)¹⁹ cytomegalovirus (CMV)¹⁴ and respiratory syncytial virus (RSV)¹⁴. In addition, surface disinfectants where BAK is the principle active component have been shown to inactivate the SARS-CoV-1 coronavirus²⁰. Virucidal activity has been demonstrated for the parental compound of CD (chlorohexidine), with alternative chlorohexidine salt form derivatives chlorohexidine gluconate and chlorohexidine acetate inactivating HIV and HSV-1^{19,21}.

Synergistic or cumulative virucidal activity of BAK and CD within the context and concentration found in Dermol 500 lotion has not previously been reported. The purpose of this study was to assess the virucidal activity of Dermol 500 and its antimicrobial components BAK and CD against influenza A virus (IAV) and SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus responsible for COVID19 disease.

131 METHODS

132

133 Cell culture

134 Madin-Darby Canine Kidney (MDCK) cells and VeroE6 cells were routinely cultured at 37°C with 5% CO₂ in
135 Dulbecco's modified Eagle's Medium (DMEM; Gibco-Life Technologies) supplemented with 10% FCS, 1%
136 penicillin/streptomycin and either Glutamax (MDCK) or NEAA (Vero E6)(Gibco-Life Technologies).
137

138 Influenza infectivity assay

139 The influenza A virus used in this study was strain A/PR8/8/34 (H1N1), henceforth referred to as IAV. The
140 virus was propagated in confluent MDCK flasks in the presence of TPCK-treated trypsin at 1 µg/ml
141 (Worthingtons Bioscience) and serum-free DMEM containing 1% penicillin/streptomycin and 1% Glutamax
142 (Gibco Life-Technologies)(SFM). MDCK cells were seeded in 6 well plates 24 to 72h prior to influenza
143 infectivity assays.
144

145 Due to their viscosity, Dermol 500 lotion and commercially available alcohol-based sanitisers were diluted
146 1:1 to 50% concentration in SFM to allow for accurate pipetting. Virus was incubated with Dermol
147 500/alcohol-based sanitisers at the final concentrations described, or with SFM alone as a control. The
148 alcohol-based hand sanitisers assessed were: 1) Cuticura Original Hand Sanitiser, 2) Lifebuoy Hand Hygiene
149 Sanitiser 3) Hygiene Vision Europe Ltd Hand Hygiene Sanitiser. Alternatively, virus was incubated with BAK
150 and CD at the concentrations described (Sigma Aldrich; CD suspended in DMSO), culture medium alone or
151 DMSO vehicle control (Supplementary Figure 1).
152

153 Virus was incubated with the treatment for the stated times at either room temperature (RT) or 32°C
154 (average skin temperature). Following incubation, SFM was added to the virus/treatment samples to a 10⁻¹
155 dilution then subject to 10-fold serial dilutions. The limit of detection was therefore 10¹ virus particles/mL.
156 Due to adverse effects of BAK and CD on cultured *in vitro* cell lines the limit of detection for BAK and CD
157 treatments between 0.05 - 0.1% was 10² virus particles/mL without filtration. Where noted, IAV was filtered
158 to remove BAK/CD post-incubation using 15 mL Amicon Ultra-15 centrifugal filter with a 50,000 molecular
159 weight cut off (UFC905008, Merck) and centrifugation (4000 x g, 10 min). Filtered virus was resuspended in
160 SFM and serially diluted as above.
161

162 Infectious virus was titred via standard plaque assay. Briefly, confluent MDCK cells were incubated with 1ml
163 of virus dilutions for 1 hour at 37°C. Virus dilutions were aspirated and cells overlaid with 3ml SFM containing
164 0.8% Avicel® (FMC BioPolymer), 0.14% BSA and TPCK-treated trypsin at 1 µg/ml (Worthingtons Bioscience).
165 After 3 days, infected cells were fixed in PBS with 8-10% formalin, stained with 0.1% toluidine blue and viral
166 plaque forming units (PFU) assessed.
167

168 SARS-CoV-2 TCID50 infectivity assay

169 The SARS-CoV-2 strain used in this study was SARS-CoV-2/England/IC19 and is henceforth referred to as
170 'SARS-CoV-2'²². Vero E6 cells were seeded into 96-well plates in supplemented DMEM for confluence the
171 next day. SARS-CoV-2 was incubated with either Dermol 500 or alcohol-based sanitiser diluted as for IAV
172 above. Alternatively, BAK and CD diluted to 0.2% in assay diluent (DMEM, 0.3% BSA, 1X NEAA, 1X
173 penicillin/streptomycin) were mixed with an equal volume of SARS-CoV-2 to a final concentration of 0.1%
174 BAK and 0.1% CD. Virus was also mixed with assay diluent in the absence of Dermol 500, alcohol-based
175 sanitisers or CD/BAK. After stated incubation period, neat sample was added to the first column of confluent
176 Vero E6 cells and Log₁₀/half-Log₁₀ dilution series immediately performed across the plate in assay diluent.
177 Four technical replicates were performed for each sample. Plates were incubated for 5 days at 37°C before
178 adding crystal violet stain (0.1% w/v) to live cells. Wells were scored for either an intact, stained cell sheet or
179 the absence of cells due to virus-induced cytopathic effect. For each condition, the Spearman-Kärber method
180 was used to calculate the 50% tissue culture infectious dose (TCID50) of the virus.
181

182 Statistical analysis

183 All data was analysed using GraphPad Prism and presented as mean ± standard deviation (mean±SD). For
184 each treatment condition, at least 2 independent biological replicates were performed.

185 **RESULTS**

186


187 **Dermol 500 exhibits virucidal activity against IAV and SARS-CoV-2 comparable to alcohol-based hand**
 188 **sanitisers.**

189


190 To assess whether Dermol 500 emollient exhibits virucidal activity, we examined the capacity of IAV and
 191 SARS-CoV-2 to infect cells following incubation with Dermol 500 (Figure 2). Dermol 500 lotion was diluted in
 192 cell culture medium to allow for accurate pipetting, therefore could only be assessed at maximum 25% of its
 193 original concentration. Even at this dilution, we observed a significant reduction in the amount of infectious
 194 IAV after 30min incubation at skin temperature 32°C (~100-fold reduction in virus particles; Figure 2A), and
 195 a similar decrease in SARS-CoV-2 infectivity after only 5min (Figure 2B). In parallel, we assessed the virucidal
 196 activity of 3 commercially available alcohol-based hand sanitisers diluted equivalently. Importantly, Dermol
 197 500 performed as well or better than these alcohol-based sanitisers at decreasing viral infectivity. The
 198 virucidal effect of Dermol 500 was concentration-dependent, performing less well at a 12.5% dilution
 199 (Supplementary Figure 2), indicating increased efficacy against viruses when Dermol 500 is used at its
 200 intended concentration. In addition, increased incubation time correlated with enhanced reduction in
 201 infectious virus.

Figure 2. Dermol 500 lotion exhibits virucidal activity against IAV and SARS-CoV-2.

A)



B)




(A) IAV was incubated with Dermol 500 or alcohol-based hand sanitisers at 25% final concentration, or medium-only control, for 5–120min at 32°C. Virus infectivity was assessed by plaque assay (n=2; mean±SD). 2-way ANOVA [treatment x time]: treatment ****P<0.0001, time P>0.05; multiple comparisons versus control: *P<0.05, **P<0.01, ***P<0.001. (B) SARS-CoV-2 was incubated with Dermol 500 or alcohol-based hand sanitisers at 25% final concentration for 5–60min, or assay diluent control for 60min, at 32°C. Virus infectivity was assessed by TCID₅₀ assay (n=2; mean±SD). 2-way ANOVA [treatment x time]: treatment ****P<0.0001, time **P<0.0032; multiple comparisons versus control: *P<0.05, **P<0.01.

202

203 **The antimicrobial agents benzalkonium chloride (BAK) and chlorohexidine dihydrochloride (CD) rapidly**
 204 **inactivate IAV and SARS-CoV-2 at the concentrations found in Dermol 500 lotion.**
 205

206 BAK and CD are considered the active antimicrobial agents in Dermol 500¹⁰, and alone have been reported
 207 to exhibit some virucidal activity^{14 18-21}. We tested their ability to inactivate IAV and SARS-CoV-2 in
 208 combination, to determine whether they contribute to the virucidal activity of Dermol 500 lotion at their
 209 intended concentration (Figure 3). Within 30 seconds of incubation with 0.1% BAK/0.1% CD the level of
 210 infectious IAV decreased 100,000-fold, and by 3 minutes infectious virus had reached undetectable levels
 211 (Figure 3A). For SARS-CoV-2, no virus-induced cytopathic effect was observed for samples incubated with
 212 0.1% BAK/0.1% CD across all incubation time frames (10² TCID₅₀/mL detection limit) indicating a >10,000-
 213 fold reduction in virus infectivity within 0.5min of contact with BAK/CD, below the limit of detection. We
 214 conclude that BAK and CD together are extremely potent virucidal agents against influenza and coronaviruses
 215 at the concentrations found in Dermol 500 lotion.

Figure 3. Benzalkonium chloride (BAK) and chlorohexidine dihydrochloride (CD) exhibit rapid virucidal activity against IAV and SARS-CoV 2 at the concentration in Dermol 500.



(A) IAV was incubated at 32°C with 0.1% BAK + 0.1% CD, or medium-only control, for 1-5min. IAV infectivity was assessed by plaque assay directly (unfiltered; 10² PFU/mL detection limit; n=2; mean±SD), or parallel samples were subject to filtration to remove BAK/CD prior to plaque assay (filtered; 10¹ PFU/mL detection limit; n=2; mean±SD). 2-way ANOVA [treatment x time]: unfiltered treatment **P=0.0031, time P>0.05; filtered treatment ***P=0.0005, time P>0.05. (B) SARS-CoV-2 was incubated at RT with 0.1% BAK + 0.1% CD for either 0.5min (n=2), 10min (n=2) or 30min (n=4), or assay diluent control for 30min (n=4)(mean±SD). Virus infectivity was assessed by TCID₅₀ assay. No virus-induced cytopathic effect was observed for samples incubated with 0.1% BAK/0.1% CD across all incubation time frames (10² TCID₅₀/mL detection limit). 2-tailed Mann-Whitney test: **P=0.002.


216
 217

218 **The antimicrobial agents BAK and CD independently inactivate IAV with different efficiencies, and act**
 219 **synergistically to disrupt viral infectivity.**
 220

221 We next investigated the virucidal activity of decreasing concentrations of BAK and CD, both in combination
 222 and independently to further characterise their efficacy (Figure 4). Within a 30 second time frame, we
 223 observed a significant decrease in IAV infectivity with the lowest concentration of BAK tested (0.0125%),
 224 indicating that amounts could be reduced in future virucidal formulations. CD alone showed no significant
 225 decrease in infectious virus over this time frame, but showed synergistic interaction with BAK by enhancing
 226 its efficacy against IAV in a time- and temperature-dependent manner (Figure 4; Supplementary Figures 3
 227 and 4). At skin temperature, CD starts to exert an independent virucidal effect at higher concentrations by 5
 228 minutes, and by 30 minutes the lowest CD concentration has reduced IAV infectivity by 100-1000 fold.
 229 0.0125% BAK/0.1% CD was the most efficient combination we tested, with IAV infectivity below detectable
 230 levels within 30 seconds (Supplementary Figure 4).


Figure 4. Viral inactivation by BAK and CD at concentrations less than 0.1%.

0.5min incubation time




IAV was incubated at 32°C with decreasing concentrations of BAK, CD or in combination. Infectivity was assessed by plaque assay (n≥2; mean±SD). 2-way ANOVA[treatment x %]: 0.5min treatment *P<0.0279, % ****P<0.0001; 5min treatment P>0.05, % ***P=0.002; 30min treatment P>0.05, % ****P<0.0001; multiple comparisons versus 0%: *P<0.05, **P<0.01, ****P<0.0001.

5min incubation time



30min incubation time



231
232

DISCUSSION AND CONCLUSIONS

233 Any employment that requires hand hygiene, exposure to irritants and PPE such as masks and gloves poses
 234 a risk of work-related skin disease, with irritant contact dermatitis the most common occupational
 235 inflammatory skin disease in Europe²³. With the prominent worldwide focus on hand hygiene and PPE during
 236 the COVID19 pandemic, increased occurrence of work-related contact dermatitis will likely extend beyond
 237 clinical settings into commercial employment industries, particularly other key workers. Occupational
 238 dermatitis is a reportable disease under UK health and safety legislation^{6,8}, and employers are legally obliged
 239 to minimise exposure to harmful substances and avoid health problems including skin conditions. The
 240 provision of emollients and soap substitutes, such as Dermol 500 lotion, are advised for treatment and
 241 prevention of dermatitis³, but not recommended currently due to a lack of evidence regarding their virucidal
 242 efficacy¹¹. This study clearly demonstrates Dermol 500, and its antimicrobial components BAK and CD, exhibit
 243 robust virucidal activity against IAV and SARS-CoV-2, enabling its use against work-related contact dermatitis
 244 during the COVID19 pandemic.

245
 246
 247
 248 Synonymous with the cumulative activity of BAK and CD against bacteria¹⁵, these compounds act
 249 synergistically to inactivate two different enveloped viruses, IAV and SARS-CoV-2. Extrapolating these results,
 250 we predict that Dermol 500 will be effective against other enveloped viruses, especially as both BAK and CD
 251 have been shown to independently inactivate the enveloped viruses HSV-1 and HIV^{19,21}. Indeed, BAK has been
 252 shown to inactivate a broad range of enveloped viruses including CCV¹⁸, CMV¹⁴, RSV¹⁴ and SARS-CoV-1²⁰.
 253 Interestingly, 0.1% BAK is a component of many commercial nasal sprays, although listed as a preservative
 254 rather than an active ingredient²⁴.

255
 256 The mechanisms underpinning BAK and CD viral inactivation are poorly understood, and beyond the scope
 257 of this paper, but both have been commonly used antimicrobials since the 1950's. They are known to disrupt
 258 the physical integrity and biochemical functions of the lipid membranes of both gram-negative and gram-
 259 positive bacteria^{12, 14, 25-27}. The synergistic activity of BAK and CD indicates they may inactivate viruses via

260 complementary mechanisms. Beyond disrupting lipid viral envelopes, BAK alone has been shown to
261 inactivate various non-enveloped viruses including human coxsackie virus¹⁹, human adenoviruses²⁸ and
262 enteroviruses¹⁴. However, BAK virucidal activity is less potent against non-enveloped viruses and requires
263 longer incubation times to achieve viral inactivation¹⁴. BAK and CD virucidal activity could also encompass
264 denaturation of viral glycoproteins required for attachment and entry. Indeed, chlorohexidine antimicrobial
265 activity has been associated with inhibition of membrane bound proteins as well as coagulation and
266 denaturation of cytoplasmic components, and may therefore access and denature viral proteins, especially
267 in the presence of BAK^{12 29}. The virucidal activity of these compounds and Dermol 500 lotion against non-
268 enveloped viruses requires further study, but we predict they will be at least as efficacious as alcohol-based
269 sanitisers, which inefficiently inactivate the majority of non-enveloped viruses^{1 30}.

270
271 To conclude, this study confirms Dermol 500 lotion and its constituents inactivate SARS-CoV-2 and the
272 common respiratory virus influenza A. This broad virucidal and antimicrobial activity of Dermol 500 emollient
273 makes it a safe and efficacious soap substitute in healthcare settings to combat the adverse effects of
274 frequent hand washing and PPE. Its use can prevent and treat work-related irritant contact dermatitis,
275 helping curb the large increases in this skin condition seen during this pandemic. In turn, this will decrease
276 instances of staff sickness absence, or restriction from clinical work due to skin disease, enhance the safe and
277 timely delivery of clinical care, and benefit staff wellbeing.

278 279 **Contributors**

280 CTS designed the study, performed laboratory experiments, analysed the data, wrote and edited the
281 manuscript. MVO and JB performed laboratory experiments and analysed the data. SR and SW provided
282 clinical data and edited the manuscript. FMR proposed the research question, provided clinical data and
283 edited the manuscript. WSB edited the manuscript and acquired funding. RSE designed the study, analysed
284 the data, wrote and edited the manuscript, and acquired funding. All authors reviewed and approved the
285 final manuscript.

286 287 **Funding**

288 This research was supported by a Wellcome Trust Sir Henry Dale Fellowship (208790/Z/17/Z) awarded to
289 Rachel S. Edgar, funding awarded to Wendy Barclay by the Oak Foundation, and conducted as part of the
290 G2P consortium funded by UKRI.

291 292 **Competing interests**

293 None declared.

294 295 **Patient consent for publication**

296 Not required.

297 298 **Ethics approval**

299 Not required

300 301 **Provenance and peer review**

302 Not commissioned; pending external peer review.

303 304 **Data availability statement**

305 Data is available on request.

306 307 **Acknowledgments**

308 We'd like to thank Dr Lucia Batty, Dr Lisa Curran and Mr James Kesson (King's College Hospital NHS
309 Foundation Trust, London) for their assistance during the preparation of this manuscript, and Dr John O'Neill
310 (MRC Laboratory of Molecular Biology, Cambridge) for helpful discussion.

311
312
313

314 **REFERENCES**

- 315
- 316 1. . WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean
317 Care Is Safer Care. Geneva2009.
- 318 2. Smedley J, Williams S, Peel P, et al. Management of occupational dermatitis in healthcare
319 workers: a systematic review. *Occup Environ Med* 2012;69(4):276-79. doi: 10.1136/oemed-
320 2011-100315
- 321 3. Smedley J, Group OD, Group BD. Concise guidance: diagnosis, management and prevention of
322 occupational contact dermatitis. *Clin Med (Lond)* 2010;10(5):487-90. doi:
323 10.7861/clinmedicine.10-5-487 [published Online First: 2010/12/02]
- 324 4. Lin P, Zhu S, Huang Y, et al. Adverse skin reactions among healthcare workers during the
325 coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions. *Br J*
326 *Dermatol* 2020;183(1):190-92. doi: 10.1111/bjd.19089 [published Online First: 2020/04/08]
- 327 5. Walsh SC, S. . Introduction of a hand dermatitis clinic to reduce occupational dermatoses during
328 the covid-19 pandemic. *medRxiv* 2021020421250767 2021 doi:
329 <https://doi.org/10.1101/2021.02.04.21250767> [published Online First: 08/02/2021]
- 330 6. Wrigglesworth F, Earl B. A guide to the Health and Safety at Work Act. Rev. ed. London: Industrial
331 Society, 1978 1974.
- 332 7. Great Britain H, Safety Executive ap. Control of substances hazardous to health : the Control of
333 Substances Hazardous to Health Regulations 2002 (as amended) : approved code of practice
334 and guidance. Sixth edition. ed.
- 335 8. Great Britain H, Safety E. A guide to the Reporting of Injuries, Diseases and Dangerous
336 Occurrences Regulations 1995, RIDDOR 95. Sudbury: HSE Books 1996.
- 337 9. Waclawski E. Disease reporting after the Reporting of Injuries, Diseases, and Dangerous
338 Occurrence Regulations (1995) (RIDDOR) is revised. *Occup Med (Lond)* 2013;63(3):168-9.
339 doi: 10.1093/occmed/kqs220 [published Online First: 2013/04/09]
- 340 10. Whitefield M. Effectiveness of a new antimicrobial emollient in the management of
341 eczema/dermatitis. *J Dermatol Treat* 1998;9(2):103-09. doi: Doi
342 10.3109/09546639809161381
- 343 11. British Society for Cutaneous Allergy BAoD. Update on occupational skin disease during the
344 coronavirus pandemic: British Society for Cutaneous Allergy & British Association of
345 Dermatologists; 2020 [updated 20/04/20. Available from:
346 <https://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=66882020>.
- 347 12. McDonnell G, Russell AD. Antiseptics and disinfectants: Activity, action, and resistance. *Clin*
348 *Microbiol Rev* 1999;12(1):147-+. doi: Doi 10.1128/Cmr.12.1.147
- 349 13. Pereira BMP, Tagkopoulos I. Benzalkonium Chlorides: Uses, Regulatory Status, and Microbial
350 Resistance. *Appl Environ Microb* 2019;85(13) doi: UNSP e00377-19
351 10.1128/AEM.00377-19
- 352 14. Belec L, Tevi-Benissan C, Bianchi A, et al. In vitro inactivation of Chlamydia trachomatis and of a
353 panel of DNA (HSV-2, CMV, adenovirus, BK virus) and RNA (RSV, enterovirus) viruses by the
354 spermicide benzalkonium chloride. *J Antimicrob Chemother* 2000;46(5):685-93. doi:
355 10.1093/jac/46.5.685 [published Online First: 2000/11/04]
- 356 15. Richards RM, McBride RJ. Enhancement of Benzalkonium Chloride and Chlorhexidine Acetate
357 Activity against Pseudomonas-Aeruginosa by Aromatic Alcohols. *J Pharm Sci-US*
358 1973;62(12):2035-37. doi: DOI 10.1002/jps.2600621232
- 359 16. Mosca A, Russo F, Miragliotta G. In vitro antimicrobial activity of benzalkonium chloride against
360 clinical isolates of Streptococcus agalactiae. *J Antimicrob Chemoth* 2006;57(3):566-68. doi:
361 10.1093/jac/dki474

- 362 17. Castillo JA, Clapes P, Infante MR, et al. Comparative study of the antimicrobial activity of
363 bis(Nalpha-caproyl-L-arginine)-1,3-propanediamine dihydrochloride and chlorhexidine
364 dihydrochloride against Staphylococcus aureus and Escherichia coli. *J Antimicrob Chemother*
365 2006;57(4):691-8. doi: 10.1093/jac/dkl012 [published Online First: 2006/02/10]
- 366 18. Saknimit M, Inatsuki I, Sugiyama Y, et al. Virucidal Efficacy of Physicochemical Treatments
367 against Coronaviruses and Parvoviruses of Laboratory-Animals. *Exp Anim Tokyo*
368 1988;37(3):341-45. doi: DOI 10.1538/expanim1978.37.3_341
- 369 19. Wood A, Payne D. The action of three antiseptics/disinfectants against enveloped and non-
370 enveloped viruses. *J Hosp Infect* 1998;38(4):283-95. doi: Doi 10.1016/S0195-6701(98)90077-
371 9
- 372 20. Rabenau HF, Kampf G, Cinatl J, et al. Efficacy of various disinfectants against SARS coronavirus.
373 *J Hosp Infect* 2005;61(2):107-11. doi: 10.1016/j.jhin.2004.12.023
- 374 21. Baqui AAMA, Kelley JJ, Jabra-Rizk MA, et al. In vitro effect of oral antiseptics on human
375 immunodeficiency virus-1 and herpes simplex virus type 1. *J Clin Periodontol* 2001;28(7):610-
376 16. doi: DOI 10.1034/j.1600-051x.2001.028007610.x
- 377 22. McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine
378 candidate induces high neutralizing antibody titers in mice. *Nat Commun* 2020;11(1):3523.
379 doi: 10.1038/s41467-020-17409-9 [published Online First: 2020/07/11]
- 380 23. Diepgen TL. Occupational skin-disease data in Europe. *Int Arch Occup Environ Health*
381 2003;76(5):331-8. doi: 10.1007/s00420-002-0418-1 [published Online First: 2003/04/12]
- 382 24. Ho CY, Wu MC, Lan MY, et al. In vitro effects of preservatives in nasal sprays on human nasal
383 epithelial cells. *Am J Rhinol* 2008;22(2):125-9. doi: 10.2500/ajr.2008.22.3154 [published
384 Online First: 2008/04/18]
- 385 25. Barrettbee K, Newbould L, Edwards S. The Membrane Destabilizing Action of the Antibacterial
386 Agent Chlorhexidine. *Fems Microbiol Lett* 1994;119(1-2):249-53.
- 387 26. Cheung HY, Wong MMK, Cheung SH, et al. Differential Actions of Chlorhexidine on the Cell Wall
388 of Bacillus subtilis and Escherichia coli. *Plos One* 2012;7(5) doi: ARTN e36659
389 10.1371/journal.pone.0036659
- 390 27. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. *J Appl*
391 *Microbiol* 2005;99(4):703-15. doi: 10.1111/j.1365-2672.2005.02664.x
- 392 28. Romanowski EG, Yates KA, Shanks RMQ, et al. Benzalkonium Chloride Demonstrates
393 Concentration-Dependent Antiviral Activity Against Adenovirus In Vitro. *J Ocul Pharmacol Th*
394 2019;35(5):311-14. doi: 10.1089/jop.2018.0145
- 395 29. Denyer SP. Mechanisms of action of antibacterial biocides. *Int Biodeter Biodegr* 1995;36(3-
396 4):227-45. doi: Doi 10.1016/0964-8305(96)00015-7
- 397 30. Golin AP, Choi D, Ghahary A. Hand sanitizers: A review of ingredients, mechanisms of action,
398 modes of delivery, and efficacy against coronaviruses. *Am J Infect Control* 2020 doi:
399 10.1016/j.ajic.2020.06.182 [published Online First: 2020/06/23]
400